Hengrui Medicine advances HRS-9813 and continues share buybacks

Jiangsu Hengrui Medicine [SSE:600276] announced its subsidiary, Guangdong Hengrui Pharmaceutical, received approval from the National Medical Products Administration for clinical trials of HRS-9813 capsules. This innovative drug, a Class 1 new drug developed in-house, targets idiopathic pulmonary fibrosis (IPF). Preclinical data indicates HRS-9813 significantly improves lung function and reduces fibrosis in mice with good safety profile. To date, the total research and development investment for HRS-9813 is approximately CNY 98.27 million.